Navigation Links
NEBA Health earns patent for integration of NEBA biomarker with clinician's ADHD evaluation
Date:8/15/2013

BOULDER, Colo., Aug. 15, 2013 /PRNewswire/ -- NEBA Health, LLC announces today that Dr. Steven M. Snyder, Research and Development Vice President, has earned US Patent 8,509,884.  The patent protects a key aspect of the NEBA system:  integrating the biomarker with a clinician's workup for ADHD.  "NEBA is not a standalone diagnostic," said Dr. Snyder.  "After the clinician's ADHD evaluation, NEBA helps them determine if the symptoms are due to ADHD or if further testing is warranted."  

"Integrating the NEBA biomarker with a clinician's initial diagnostic impression can bring a clinician's diagnosis more in line with that of multidisciplinary team," said Dr. Snyder.  Research supports that compared to a clinician alone, a multidisciplinary team is better able to determine if ADHD-like symptoms are accounted for by another condition. 

In order to diagnose ADHD, a clinician not only observes criteria regarding behavioral symptoms and impairment, but also must determine whether symptoms would be better accounted for by another condition.  Because ADHD shares symptoms with other disorders, the diagnosis may be difficult.  According to the US Center for Disease Control and Prevention (CDC), 9.5% of all children and adolescents have an ADHD diagnosis.  The ADHD diagnosis rate is increasing.  CDC states that rates of ADHD diagnosis increased an average of 3% per year from 1997 to 2006 and an average of 5.5% per year from 2003 to 2007.

"In their ADHD evaluation, clinicians may be challenged in the current medical environment to determine the primary diagnosis when overlapping symptoms are present," said Howard Merry, President of NEBA Health.  "We are delighted that the USPTO has awarded Dr. Snyder the patent.  It covers NEBA's core technology, and it's another validation point for the 7 years we spent developing and validating NEBA." 

About NEBA Health

NEBA Health has developed the first FDA approved medical device based on brain waves to help assess ADHD.  The device, NEBA, is cleared in the USA (K112711), CE marked, and Health Canada licensed.  To our knowledge, the NEBA FDA validation study is the largest ADHD diagnostic study of this nature ever conducted (275 subjects at 13 clinical sites).  We have ongoing work in ADHD, depression, and dementia.  Our technologies are NIEAAs (Neuropsychiatric Interpretive EEG-based Assessment Aids).  NEBA Health is privately held.


'/>"/>
SOURCE NEBA Health, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. First students at new College of Pharmacy to begin classes next week at UNT Health Science Center
2. mHealth Identified as Critical Strategy in Medication Adherence Programs
3. iSALUS Healthcare Expands Revenue Cycle Management Services with Billnet Solutions
4. Natus Neurology Incorporated Receives 510(k) & Health Canada Clearance And Launches New Electrodiagnostic System In U.S. & Canada
5. Millennium HealthCare Inc. Featured in Forbes
6. Wolters Kluwer Health Launches Nursing Drug Handbook Specialty Apps
7. PinnacleHealth, Meridian Health Select Perioperative IT from Surgical Information Systems
8. Hospira to Present at the Morgan Stanley Global Healthcare Conference
9. Chinas Strong Economic Growth and Healthcare Investments Generate Success for CPhI
10. Endo and Metamark Announce Sale of HealthTronics Laboratory Solutions
11. Real Time Location Systems (RTLS) Market in Healthcare Industry 2011 - 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... 10, 2017  NDS received FDA 510(k) clearance in May 2017 ... display stand specifically designed for endoscopy environments. An innovative secondary monitor ... clinical solution to support the improvement of patient outcomes, procedural efficiency, ... ... ...
(Date:10/4/2017)... Korea , Oct. 4, 2017  South Korean-based ... next-generation CPR training aide "cprCUBE" on Kickstarter. The device ... compression during cardiac arrests with better efficiency compared to ... also offers real-time feedback on efficacy of the compression ... crowdfunding campaign has a goal to raise $5,000. ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ... viewers the lowdown on sciatica in a new episode of "Success Files," which ... current events and innovation and investigates each subject in-depth with passion and integrity. ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), an ... showcase a range of technology and learning solutions at the 68th Annual American ... to be held October 14–18, 2017 at the Mandalay Bay Resort in Las ...
(Date:10/12/2017)... ... 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of ... innovative new design of the shoulder pad. The shoulder pad provides optimal support ... your pain while using cold therapy. By utilizing ice and water that is circulated ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, the Los ... article to the newly revamped Cosmetic Town journal section, featuring articles ... procedure known as Follicular Unit Extraction (FUE). , Dr. Mohebi says ...
(Date:10/12/2017)... GRAND RAPIDS, Mich. (PRWEB) , ... October 12, ... ... OnSite Wellness, has been named one of Michigan’s 2017 Best and Brightest in ... Best and Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 ...
Breaking Medicine News(10 mins):